https://www.selleckchem.com/pr....oducts/epoxomicin-bu
evelopment, and there were a notable number of approvals that occurred using the support of the grants program. There was a suggested association between collaboration and successful outcomes. Efficient and innovative trial designs and collaboration among stakeholders appear vital to continue to effectively bring products to rare disease patients. Ongoing program assessments will ensure that the funding continues to be used to optimally meet the treatment needs of the rare disease community. Taenia solium taeniasis/cysticerc
Like
Comment
Share
